Category Archives: Canadian Regulatory Affairs

What’s New Health Canada? February 2017

By Amelie Rodrigue-Way, Ph.D., RAC (CAN), Associate Director, Regulatory Strategy, and Christine Straccini, B.Sc., Regulatory Associate; Cato Research Canada   What’s New in: Therapeutic Products Directorate: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/update-miseajour/index-eng.php Biologics and Genetic Therapies Directorate: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/update-miseajour/index-eng.php Medical Devices: http://www.hc-sc.gc.ca/dhp-mps/md-im/update-miseajour/index-eng.php Natural and Non-prescription Health … Continue reading

Posted in Canadian Regulatory Affairs, Cato Research | Tagged , | Leave a comment

Transparency Initiatives at Health Canada

By Amelie Rodrigue-Way, Ph.D., RAC (CAN), Associate Director, Regulatory Strategy for Cato Research Canada. As part of the Regulatory Transparency and Openness Framework (http://www.hc-sc.gc.ca/home-accueil/rto-tor/index-eng.php), Health Canada has committed to provide greater transparency and openness to further strengthen trust in their … Continue reading

Posted in Canadian Regulatory Affairs, Cato Research, Clinical Trials, Drug Development, Health Canada | Tagged , , | Comments Off on Transparency Initiatives at Health Canada

Credentialing Developments at Cato Research

In 2014, approximately 20-25 members of the global CATO staff participated in extensive training sessions devoted to Canadian Regulatory Affairs. This effort was led by Amelie Rodrigue-Way, PhD from the Montreal office of CATO Research Ltd. During the last 8 … Continue reading

Posted in Canadian Regulatory Affairs, FDA, Regulatory Strategy, Regulatory Submissions | Tagged , , , | Comments Off on Credentialing Developments at Cato Research